The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a mid-stage trial for its experimental ...

Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it ... On Jan. 15, the FDA approved Lilly's Omvoh for the treatment of Crohn's disease. In the Vivid-1 trial with patients who didn't ...

Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Eli Lilly and Company ...

Shares of Tectonic Therapeutic (NASDAQ:TECX) plunged on Tuesday after a federal website on clinical trials indicated that Eli Lilly (NYSE:LLY) has terminated a mid-stage trial for its experimental ...